Jason Shafrin

20PUBLICATIONS
28CO-AUTHORS
Epidemiological modellingHaematological tumoursNaturopathyCancer therapy (excl. chemotherapy and radiation therapy)Econometric and statistical methods
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Aug 20, 2026
Valuing Dementia Interventions Under Uncertainty: A Comparison of Generalized and Risk-Adjusted Cost Effectiveness to Traditional Cost-Effectiveness Analyses.

|Jul 14, 2026
Financial Impact of Treatment Choice in Chronic Myeloid Leukemia: A Comparison of Later Generation TKIs versus Imatinib from Patient and Payer Perspectives.

|Feb 23, 2026
Pulmonary Arterial Hypertension and Cancer: Unveiling Parallels in Epidemiology, Clinical Pathways, and Therapeutic Strategies.

Karim El-Kersh, Nadine Zawadzki, Catelyn Coyle

|Jan 10, 2026
Cost per responder analysis of iptacopan versus eculizumab and ravulizumab in treatment of paroxysmal nocturnal hemoglobinuria: implications for decision-making.

Kyi-Sin Than, Jason Shafrin, Sanjana Muthukrishnan

|Nov 26, 2025
Chronic myeloid leukemia treatment intolerance imposes additional resource and economic burden on oncology practices in the United States.

Jason Shafrin, Kejal Jadhav, Cheryl Warren

|Nov 26, 2025
Quantifying treatment value under IRA: a case study of rifaximin for the treatment of overt hepatic encephalopathy using QALY and non-QALY measures.

Shanshan Wang, Leonardo Passos Chaves, Olamide Olujohungbe

Pageof 4

Frequent Collaborators

2 joint publications

Sanjana Muthukrishnan

2 joint publications

Kyi-Sin Than

1 joint publications

Suepattra G May

1 joint publications

Caroline Huber